Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SEQUENTIAL ADMINISTRATION OF RECOMBINANT HUMAN INTERLEUKIN-3 AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR MALIGNANT-LYMPHOMA - A PHASE I II MULTICENTER STUDY/
Autore:
FAY JW; LAZARUS H; HERZIG R; SAEZ R; STEVENS DA; COLLINS RH; PINEIRO LA; COOPER BW; DICESARE J; CAMPION M; FELSER JM; HERZIG G; BERNSTEIN SH;
Indirizzi:
BAYLOR UNIV,MED CTR,CHARLES A SAMMONS CANC CTR,3500 GASTON AVE,SAMMONS TOWER,SUITE 410 DALLAS TX 75246 CASE WESTERN RESERVE UNIV,UNIV IRELAND CANC CTR CLEVELAND OH 00000 UNIV LOUISVILLE LOUISVILLE KY 40292 OKLAHOMA MEM HOSP & CLIN OKLAHOMA CITY OK 00000 SANDOZ INC,PHARMACEUT,CYTOKINE DEV UNIT E HANOVER NJ 00000 ROSWELL PK CANC INST BUFFALO NY 00000
Titolo Testata:
Blood
fascicolo: 7, volume: 84, anno: 1994,
pagine: 2151 - 2157
SICI:
0006-4971(1994)84:7<2151:SAORHI>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIGH-DOSE CHEMOTHERAPY; PROGENITOR CELLS; PLATELET RECOVERY; G-CSF; PRIMATES; ETOPOSIDE; CYCLOPHOSPHAMIDE; HEMATOPOIESIS; CARMUSTINE; CISPLATIN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
32
Recensione:
Indirizzi per estratti:
Citazione:
J.W. Fay et al., "SEQUENTIAL ADMINISTRATION OF RECOMBINANT HUMAN INTERLEUKIN-3 AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR MALIGNANT-LYMPHOMA - A PHASE I II MULTICENTER STUDY/", Blood, 84(7), 1994, pp. 2151-2157

Abstract

Preclinical studies of recombinant human interleukin-3 (rhIL-3) and granulocyte-macrophage colony-stimulating factor (rhGM-CSF) have shown enhancement of multilineage hematopoiesis when administered sequentially. This study was designed to evaluate the safety, tolerability, and biologic effects of sequential administration of rhIL-3 and rhGM-CSF after marrow ablative cytotoxic therapy and autologous bone marrow transplantation (ABMT) for patients with malignant lymphoma. Thirty-seven patients (20 patients with non-Hodgkin's lymphoma and 17 patients withHodgkin's disease) received one of four different treatment regimens before ABMT. Patients were entered in one of four study groups to receive rhIL-3 (2.5 or 5.0 mu g/kg/day) administered by subcutaneous injection for either 5 or 10 days starting 4 hours after the marrow infusion. Twenty-four hours after the last dose of rhIL-3, rhGM-CSF (250 mu g/m(2)/d as a 2-hour intravenous infusion) administration was initiated. rhGM-CSF was administered daily until the absolute neutrophil count (ANC) was greater than or equal to 1,500/mu L for 3 consecutive days or until day 27 posttransplant. The most frequent adverse events in thetrial included nausea, fever, diarrhea, mucositis, vomiting, rash, edema, chills, abdominal pain, and tachycardia. Three patients were removed from the study because of chest, skeletal, and abdominal pain feltto be probably related to study drug. Four patients died during the study period because of complications unrelated to either rhIL-3 or rhGM-CSF. The median time to recovery of neutrophils (ANC greater than orequal to 500/mu L) and platelets (platelet count greater than or equal to 20,000/mu L) was 14 and 15 days, respectively. There were fewer days of platelet transfusions than seen in historical control groups using rhGM-CSF, rhG-CSF, or rhIL-3 alone. In addition, there were fewer days of red blood cell transfusions compared with historical controls using no cytokines or rhGM-CSF. These data indicate that the sequential administration of rhIL-3 and rhGM-CSF after ABMT is safe and generally well-tolerated and results in rapid recovery of multilineage hematopoiesis. (C) 1994 by The American Society of Hematology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 06:51:27